Although Daniel George, MD, of the Duke Cancer Institute, sees value in cancer vaccines and expects they will start showing more benefit to patients, he acknowledges that a barrier to widespread use of cancer vaccines is that they don't show an immediate response.
Although Daniel George, MD, of the Duke Cancer Institute, sees value in cancer vaccines and expects they will start showing more benefit to patients, he acknowledges that a barrier to widespread use of cancer vaccines is that they don't show an immediate response.
Transcript
What is your outlook on cancer vaccines, and what do you think has been a barrier to preventing widespread use?
So immunotherapy is exciting because of the checkpoint inhibitors, but let's not forget that there is absolutely more to the immune system than PD-1, PD-L1 target. And I personally believe that cancer vaccines will show more and more benefit in the future in patients. In prostate cancer we have the sipuleucel-T strategy, which is a cancer vaccine of sorts, where we're activating autologous antigen-presenting cells to stimulate the immune system. And I do see a role for both stimulating the immune system as well as releasing checkpoints in combination or in sequence in the future.
I think one of the problems has been that with vaccines they take time to work. And because of that we don't typically see an immediate response. And in oncology, we're kind of trained to a culture of looking for a response to agents to guide our practice, whether it be chemotherapy, hormonal therapy, or even now checkpoint inhibitors. So I do see that as somewhat of a stumbling block in being able to show the value.
Ultimately, vaccines should show an improvement in overall survival, of disease-free survival in the adjuvant setting, or what have you. So I do look forward to them in the future, but I think they're going to take longer, slower trials to show their benefit.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More